:: LMS Chat ::

:: Leiomyosarcoma (LMS) Defined ::

Leiomyosarcoma (Gr. Leio- =smooth, myo- = muscle, sarcoma = fleshy growth) is a type of sarcoma which is a neoplasm of smooth muscle. (When a uterine neoplasm is benign, it is a leiomyoma.) Smooth muscle cells make up the involuntary muscles, which are found in most parts of the body: in uterus, stomach and intestines, walls of all blood vessels, and skin. It is therefore possible for leiomyosarcomas to appear at any site in the body. It is however most commonly found in the stomach, small intestine and retroperitoneum.

Leiomyosarcoma is a very rare cancer. It makes up 5-10% of soft tissue sarcomas, which are in themselves rare cancers.

:: About Leiomyosarcoma ::

Leiomyosarcoma is a form of cancer that affects the smooth muscle of the body. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body.

LMS is a type of sarcoma which is a neoplasm of smooth muscle. Smooth muscle cells make up the involuntary muscles, which are found in most parts of the body: in the uterus, stomach and intestines, walls of all blood vessels, and skin.

Leiomyosarcoma is a very rare cancer. It makes up 7% of soft tissue sarcomas; in all, LMS affects 4 out of 1,000,000 people.

Presently there is no cure. Remission can be attained, but this rare cancer can reappear at any time. Because of its rarity, few doctors know how to treat it and it attracts very little research.

Showing posts with label LMSNews. Show all posts
Showing posts with label LMSNews. Show all posts

Saturday, August 29, 2009

‘Better Than Ever’ looking for new ‘Sole-Mates’

By Mike Touzeau, Special to the Green Valley News
Published: Tuesday, August 25, 2009 4:14 PM MST
You probably know someone who has battled cancer — perhaps even someone who lost.

The disease affects virtually everyone, directly or indirectly, which is why “Better Than Ever” (BTE) begins its 10 year at the forefront of a local campaign that has attracted hundreds of participants while raising hundreds of thousands of dollars for the Arizona Cancer Center.

It’s likely most people in the Green Valley/Sahuarita area have already heard about the BTE “Sole-Mates,” a group that continues to promote fitness as prevention for cancer, but may not be aware they too can join them in the fight.

Leaders Suzie Cherry, Barbara Powell, Sandy Bird and Kathy Wong are once again inviting anyone who wants a chance to join their army of “battling BTE’s” to enjoy their kickoff orientation Tuesday, Sept. 1, at 5:30 p.m. at Arizona Family Restaurant in Green Valley.

Training sessions in a “welcoming, non-competitive atmosphere” begin a week later, so it’s an opportunity for those who want to “have fun, be fit, and fight cancer,” as their brochures state, while at the same time get a chance to meet some courageous and dedicated supporters of today’s cutting edge treatments and tomorrow’s cures.

Virtually every “Sole-Mate” has lost someone to cancer, and that reality was driven home with even more agonizing certainty when one of their most active members succumbed to leiomyosarcoma in March.


“She fought a long, hard battle,” said Wong of her good friend Chris Portmann, who was only 58. “She was the epitome of living with her cancer, and living life to the fullest.”

Portmann finished the 2007 Tucson half-marathon, one of BTE’s major fund-raising events, while struggling with the disease — no small feat.

“Unfortunately, she was one of those in a million who get this type of cancer,” Bird said, “and she was one-in-a-million as a person.”

Bird had never been in any kind of fitness or walking program before she joined the group last year about this time, but because of the support from her training leaders and friends, she was able to finish the half-marathon in 2008.

“I didn’t think I would ever make it,” she admits, but she recalls the times that people just like Portmann encouraged her to keep going when she wanted to turn back, which is why she wants to continue to participate to remember her friend.

“It was first in her honor,” Bird said, “and now it’s in her memory.”

BTE trains participants in a 90-day program to run or walk their choice of events and distances, which include the CATwalk 10k (6.2 miles) on Saturday, Nov. 14, the Tucson half-marathon of 13.1 miles on Sunday, Dec. 13 (a Catalina State Park event in April and a Cinco de Mayo event), or they can cycle in the El Tour de Tucson Saturday Nov. 21.

Biking was just added three years ago to the BTE program in Tucson.

“We’d really like a biking group to get started in Green Valley/Sahuarita with BTE,” Wong said.

BTE’s program is designed for walkers, runners, and cyclists of all ages, and they include group workouts, coaching, a lecture series on healthy living, social functions, and a weekly newsletter with tips and information.

All money raised goes directly to research grants for the Arizona Cancer Center.

BTE raised $100,000 in 2008-09, Wong said.

The training sessions start every Saturday from either the Desert Hills or Santa Rita Springs recreations centers, she said, adding that they all head out for breakfast afterward.

“It’s a great source of camaraderie for the women,” she declared, “and we’d like to have more men out there.”

Since August of 2000, BTE has raised more than $1,000,000 and 2,800 participants of all ages have crossed the finish line — like Alice Slater, 79, a breast and colon cancer survivor who still does most of the events.

“I’m so grateful that I’m able to do this at all, considering how my health has been,” Slater said.

If you would like to join in the fight, Wong said, just call her at 625-0159 or Sandy Bird at 399-1511, and you can get more information at www.arizonabte.org.

Mike Touzeau is a freelance writer for the Green Valley News.

Thursday, June 4, 2009

Prospective Randomized Trial

A prospective randomized trial comparing patient-
controlled epidural analgesia to patient-controlled
intravenous analgesia on postoperative pain control
and recovery after major open gynecologic cancer
surgery

http://snipurl.com/jf4ae [www_sciencedirect_com]

Methods
A randomized controlled clinical trial included
women undergoing laparotomy for a gynecologic
disorder. Patients were randomized to postoperative
IV morphine PCA (control arm) or to postoperative
morphine–bupivacaine PCEA (treatment arm).
Postoperative outcomes such as pain, and length of
hospital stay were compared with an intention-to-
treat analysis. The primary endpoint was
postoperative pain at rest and when coughing —
assessed by a 10-point visual analog scale (VAS).

Results
Between 9/04 and 6/07, 153 patients were randomized
and 135 were evaluable (PCEA = 67; PCA = 68). Over
75% of the women in this study had gynecologic
cancer. Patients in the PCEA arm had significantly
less postoperative pain at rest on Day 1 and during
the first 3 postoperative days when coughing
compared to the PCA arm (P < 0.05). The mean pain
score at rest on Day 1 was 3.3 for the PCEA group
compared to 4.3 for the PCA group (P = 0.01).
Overall, postoperative pain at rest and while
coughing in the first 6 days was less in women
treated with PCEA compared to PCA (P < 0.003).

Conclusions
PCEA offers superior postoperative pain control
after laparotomy for gynecologic surgery compared to
traditional IV PCA. Women requiring major open
surgery for gynecologic cancer should be offered
PCEA for postoperative pain management if there are
no contraindications.

Sunday, May 17, 2009

PET Scans and LMS

http://www.steinfurthinstruments.com/pictures/LMS_Gesamtansicht_co_jn.jpg

Fluorodeoxyglucose positron emission tomography in leiomyosarcoma:
imaging characteristics.

Nucl Med Commun. 2009 May 13. [Epub ahead of print]

Punt SE, Eary JF, Oʼsullivan J, Conrad EU.
aDepartments of Radiology and Orthopedics, University of Washington,
Seattle, Washington, USA bDepartment of Statistics, University
College, Cork, Ireland.

OBJECTIVE: Leiomyosarcoma, a malignant neoplasm of smooth muscle,
accounts for 7% of the sarcomas. Patients with leiomyosarcoma tumors
have an average survival of 5 years. These tumors, which are derived
from mesenchymal tissues, are difficult to diagnose, and treatment
options remain controversial. The relatively rare incidence of this
soft tissue sarcoma subtype has limited the number of patients
available for studies and research. This study examines whether the
imaging characteristics of positron emission tomography (PET) with
radiolabeled fluorodeoxyglucose (FDG) provide a reliable, noninvasive
means to predict tumor behavior in patients with leiomyosarcomas.

METHODS: [F]-FDG-PET was performed on the tumors of participating
patients before the neoadjuvant chemotherapy or resection, and a
maximum tumor standard uptake value (SUVmax) was calculated.

RESULTS: The SUVmax was correlated with tumor grade (P=0.001) and
tumor size as greatest dimension (P=0.004). Analysis of these data
indicated the potential effectiveness of FDG-PET imaging in predicting
tumor grade.

CONCLUSION: In leiomyosarcoma, the SUVmax from FDG-PET is a likely
predictor of tumor behavior. The results of this study suggest that a
large (by greatest dimension) intermediate grade tumor is expected to
have the same predicted outcome as a high-grade tumor and should be
treated in the same manner, as they share the same prognosis by
definition of tumor grade. Improvements made in the clinical treatment
of leiomyosarcomas by use of FDG-PET imaging data may lead to an
increase in patient survival.

PMID: 19440162

Myocardin gene amplification in most human retroperitoneal LMS

Strong smooth muscle differentiation is dependent on myocardin gene
amplification in most human retroperitoneal leiomyosarcomas.

Cancer Res. 2009 Mar 15;69(6):2269-78. Epub 2009 Mar 10.

Pérot G, Derré J, Coindre JM, Tirode F, Lucchesi C, Mariani O, Gibault
L, Guillou L, Terrier P, Aurias A.
Genetics and Biology of Cancers, Institut Curie, Paris, France.

Myocardin (MYOCD), a serum response factor (SRF) transcriptional
cofactor, is essential for cardiac and smooth muscle development and
differentiation. We show here by array-based comparative genomic
hybridization, fluorescence in situ hybridization, and expression
analysis approaches that MYOCD gene is highly amplified and
overexpressed in human retroperitoneal leiomyosarcomas (LMS), a very
aggressive well-differentiated tumor. MYOCD inactivation by shRNA in a
human LMS cell line with MYOCD locus amplification leads to a dramatic
decrease of smooth muscle differentiation and strongly reduces cell
migration. Moreover, forced MYOCD expression in three undifferentiated
sarcoma cell lines and in one liposarcoma cell line confers a strong
smooth muscle differentiation phenotype and increased migration
abilities. Collectively, these results show that human retroperitoneal
LMS differentiation is dependent on MYOCD
amplification/overexpression, suggesting that in these
well-differentiated LMS, differentiation could be a consequence of an
acquired genomic alteration. In this hypothesis, these tumors would
not necessarily derive from cells initially committed to smooth muscle
differentiation. These data also provide new insights on the cellular
origin of these sarcomas and on the complex connections between
oncogenesis and differentiation in mesenchymal tumors.

PMID: 19276386

Early Outcomes of Soft Tissue Sarcomas Presenting With Metastases and Treated With Chemotherapy

Am J Clin Oncol. 2009 May 8.

King JJ, Fayssoux RS, Lackman RD, Ogilvie CM.
From the *Department of Orthopedic Surgery, Drexel University,
Philadelphia, PA; and daggerDepartment of Orthopedic Surgery,
University of Pennsylvania, Philadelphia, PA.

OBJECTIVES:: The purpose of this study is to describe outcomes for
patients with metastatic soft tissue sarcoma treated with
chemotherapy.

METHODS:: We retrospectively reviewed the records of 383 soft tissue
sarcoma patients treated at our institution from 1997 to 2006.
Thirty-five patients met the inclusion criteria-metastatic disease on
presentation; primary tumor outside the abdomen; treatment with
chemotherapy; and minimum follow-up of 3 months. Treatments were
individualized and determined by a multidisciplinary oncology team.
Patient survival was calculated from the diagnostic biopsy to the date
of death or last follow-up using the Kaplan-Meier method.

RESULTS:: Mean age was 47 years (range 17-74 years).

Most common tumors involved were MFH and leiomyosarcoma.

Sixteen of 35 (46%) patients had died at last follow-up. Mean patient
survival was 24 months (range 4-102). The 2-year and 5-year survival
rates were 64% and 24%, respectively. Twenty-nine patients (83%)
presented with pulmonary metastasis, 6 with bone metastases (17%), 4
with regional node metastases (11%), and 4 with soft tissue metastases
(11%). Survival was the same for those with pulmonary and only
extrapulmonary metastases. The 10 patients with complete resection or
complete chemotherapy response of all detectable lesions had longer
mean survival (34 months) than the 25 patients who had partial/no
resection or response (20 months) (P = 0.02).

CONCLUSIONS:: Soft tissue sarcoma patients presenting with metastatic
disease have a low survival rate, but complete eradication of tumor
correlated with longer survival. Longer-term studies especially those
tracking the outcome of complete responders and those completely
resected will help determine the efficacy of chemotherapy.

PMID: 19433963 [PubMed - as supplied by publisher]